Thus far, the effect of tirzepatide on cardiovascular risk factors has indicated improvements in lipids, lipoprotein profiles, glucose control, body weight, blood pressure, and several biomarkers of inflammation in adults with overweight or obesity both with and without T2D (Tables 1, 2, 3, 4)
Similarly, the MIC of free ceftazidime (CAZ) varied between 32512 g/mL, whereas LipoOA-CAZ decreased MIC to 28 g/mL [155]
These include dose optimization (if you are not yet at the maximum therapeutic dose), dietary modifications (recalculating caloric needs for your current weight), increasing physical activity (particularly resistance training to preserve metabolic rate), and addressing sleep and stress factors that influence cortisol and insulin
Seventy-seven percent (77%) of participants were female, and 23% were male